WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H575328
CAS#: 186694-02-0 (hydrochloride hydrate)
Description: Fasudil hydrochloride hydrate is an HCl salt of Fasudil -- a Rho-kinase (ROCK) inhibitor that has been shown to be effective in hindering the development of mature Cerebral Cavernous Malformation (CCM) lesions as well as reducing portal venous pressure in cirrhotic rats.
Hodoodo Cat#: H575328
Name: Fasudil hydrochloride hydrate
CAS#: 186694-02-0 (hydrochloride hydrate)
Chemical Formula: C28H38Cl2N6O5S2
Exact Mass: 672.17
Molecular Weight: 673.670
Elemental Analysis: C, 49.92; H, 5.69; Cl, 10.52; N, 12.48; O, 11.87; S, 9.52
Related CAS #: 105628-07-7 (HCl) 103745-39-7 (free base) 186694-02-0 (hydrochloride hydrate)
Synonym: Eril-S; Fasudil hydrochloride hemihydrate; Fasudil hydrochloride hydrate
IUPAC/Chemical Name: 1H-1,4-Diazepine, hexahydro-1-(5-isoquinolinylsulfonyl)-, monohydrochloride, hydrate (2:1)
InChi Key: AACOJGPCMIDLEY-UHFFFAOYSA-N
InChi Code: InChI=1S/2C14H17N3O2S.2ClH.H2O/c2*18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14;;;/h2*1,3-5,7,11,15H,2,6,8-10H2;2*1H;1H2
SMILES Code: O.Cl.Cl.O=S(=O)(N1CCCNCC1)c2cccc3cnccc23.O=S(=O)(N4CCCNCC4)c5cccc6cnccc56
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 673.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1. Shenkar R, Shi C, Austin C, Moore T, Lightle R, Cao Y, Zhang L, Wu M, Zeineddine HA, Girard R, McDonald DA, Rorrer A, Gallione C, Pytel P, Liao JK, Marchuk DA, Awad IA. RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke. 2017 Jan;48(1):187-194. doi: 10.1161/STROKEAHA.116.015013. Epub 2016 Nov 22. PMID: 27879448; PMCID: PMC5183488.
2. McDonald DA, Shi C, Shenkar R, Stockton RA, Liu F, Ginsberg MH, Marchuk DA, Awad IA. Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation disease. Stroke. 2012 Feb;43(2):571-4. doi: 10.1161/STROKEAHA.111.625467. Epub 2011 Oct 27. PMID: 22034008; PMCID: PMC3265629.
3. Fukuda T, Narahara Y, Kanazawa H, Matsushita Y, Kidokoro H, Itokawa N, Kondo C, Atsukawa M, Nakatsuka K, Sakamoto C. Effects of fasudil on the portal and systemic hemodynamics of patients with cirrhosis. J Gastroenterol Hepatol. 2014 Feb;29(2):325-9. doi: 10.1111/jgh.12360. PubMed PMID: 24033356.
